<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240201211429&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240201211429&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Fri, 02 Feb 2024 02:14:30 +0000</lastbuilddate>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Seeking for Regulatory Mechanisms of Phospholamban Expression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38300986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):266-268. doi: 10.1161/CIRCRESAHA.124.324109. Epub 2024 Feb 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38300986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38300986</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324109>10.1161/CIRCRESAHA.124.324109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38300986</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Cecilia Mundiña-Weilenmann</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Seeking for Regulatory Mechanisms of Phospholamban Expression</dc:title>
<dc:identifier>pmid:38300986</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324109</dc:identifier>
</item>
<item>
<title>Where Do We Go From Here: Reflections on a Century in Women's Cardiovascular Health Research, 1924-2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38300985/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):247-251. doi: 10.1161/CIRCRESAHA.123.323182. Epub 2024 Feb 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38300985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38300985</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323182>10.1161/CIRCRESAHA.123.323182</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38300985</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Natalie A Bello</dc:creator>
<dc:creator>Susan Cheng</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Where Do We Go From Here: Reflections on a Century in Women's Cardiovascular Health Research, 1924-2024</dc:title>
<dc:identifier>pmid:38300985</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323182</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38300984/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):246. doi: 10.1161/RES.0000000000000656. Epub 2024 Feb 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38300984/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38300984</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000656>10.1161/RES.0000000000000656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38300984</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38300984</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000656</dc:identifier>
</item>
<item>
<title>Aging Two-Step: SOX9's Influence on Vascular Stiffness and Senescence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38300983/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):325-327. doi: 10.1161/CIRCRESAHA.124.324212. Epub 2024 Feb 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38300983/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38300983</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324212>10.1161/CIRCRESAHA.124.324212</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38300983</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Parya Behzadi</dc:creator>
<dc:creator>Cynthia St Hilaire</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Aging Two-Step: SOX9's Influence on Vascular Stiffness and Senescence</dc:title>
<dc:identifier>pmid:38300983</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324212</dc:identifier>
</item>
<item>
<title>Mechanism of Ventricular Tachycardia Occurring in Chronic Myocardial Infarction Scar</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38300981/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>Cardiac arrest is the leading cause of death in the more economically developed countries. Ventricular tachycardia associated with myocardial infarct is a prominent cause of cardiac arrest. Ventricular arrhythmias occur in 3 phases of infarction: during the ischemic event, during the healing phase, and after the scar matures. Mechanisms of arrhythmias in these phases are distinct. This review focuses on arrhythmia mechanisms for ventricular tachycardia in mature myocardial scar. Available data...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):328-342. doi: 10.1161/CIRCRESAHA.123.321553. Epub 2024 Feb 1.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac arrest is the leading cause of death in the more economically developed countries. Ventricular tachycardia associated with myocardial infarct is a prominent cause of cardiac arrest. Ventricular arrhythmias occur in 3 phases of infarction: during the ischemic event, during the healing phase, and after the scar matures. Mechanisms of arrhythmias in these phases are distinct. This review focuses on arrhythmia mechanisms for ventricular tachycardia in mature myocardial scar. Available data have shown that postinfarct ventricular tachycardia is a reentrant arrhythmia occurring in circuits found in the surviving myocardial strands that traverse the scar. Electrical conduction follows a zigzag course through that area. Conduction velocity is impaired by decreased gap junction density and impaired myocyte excitability. Enhanced sympathetic tone decreases action potential duration and increases sarcoplasmic reticular calcium leak and triggered activity. These elements of the ventricular tachycardia mechanism are found diffusely throughout scar. A distinct myocyte repolarization pattern is unique to the ventricular tachycardia circuit, setting up conditions for classical reentry. Our understanding of ventricular tachycardia mechanisms continues to evolve as new data become available. The ultimate use of this information would be the development of novel diagnostics and therapeutics to reliably identify at-risk patients and prevent their ventricular arrhythmias.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38300981/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38300981</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.321553>10.1161/CIRCRESAHA.123.321553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38300981</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>J Kevin Donahue</dc:creator>
<dc:creator>Jonathan Chrispin</dc:creator>
<dc:creator>Olujimi A Ajijola</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mechanism of Ventricular Tachycardia Occurring in Chronic Myocardial Infarction Scar</dc:title>
<dc:identifier>pmid:38300981</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.321553</dc:identifier>
</item>
<item>
<title>Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38299369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS: Taken together, these results establish a novel human-like murine model of PH that has long been lacking in the field, which can be broadly used for future mechanistic and translational studies. These data also indicate that targeting endothelial DHFR deficiency represents a novel and robust therapeutic strategy for the treatment of PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 1. doi: 10.1161/CIRCRESAHA.123.323090. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary hypertension (PH) is a progressive disorder characterized by remodeling of the pulmonary vasculature and elevated mean pulmonary arterial pressure, resulting in right heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Here, we show that direct targeting of the endothelium to eNOS (endothelial nitric oxide synthase) with DAHP (2,4-diamino 6-hydroxypyrimidine; an inhibitor of GTP cyclohydrolase 1, the rate-limiting synthetic enzyme for the critical eNOS cofactor tetrahydrobiopterin) induces human-like, time-dependent progression of PH phenotypes in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Critical phenotypic features include elevation in mean pulmonary arterial pressure, right ventricular systolic blood pressure, and right ventricular/(LV+S) ratio; extensive vascular remodeling of pulmonary arterioles with increased medial thickness/perivascular collagen deposition and increased expression of PCNA (proliferative cell nuclear antigen) and alpha-actin; increased total and mitochondrial superoxide production, reduced tetrahydrobiopterin, and nitric oxide bioavailabilities; and formation of an array of human-like vascular lesions. Intriguingly, novel in-house generated endothelial-specific dihydrofolate reductase (DHFR) transgenic mice were completely protected from the pathophysiological and molecular features of PH upon DAHP treatment or hypoxia. Furthermore, DHFR overexpression with a pCMV-DHFR plasmid transfection in mice after initiation of DAHP treatment completely reversed PH phenotypes. DHFR knockout mice spontaneously developed PH at baseline and had no additional deterioration in response to hypoxia, indicating an intrinsic role of DHFR deficiency in causing PH. RNA-sequencing experiments indicated great similarity in gene regulation profiles between the DAHP model and patients with human PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Taken together, these results establish a novel human-like murine model of PH that has long been lacking in the field, which can be broadly used for future mechanistic and translational studies. These data also indicate that targeting endothelial DHFR deficiency represents a novel and robust therapeutic strategy for the treatment of PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38299369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38299369</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323090>10.1161/CIRCRESAHA.123.323090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38299369</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Priya Murugesan</dc:creator>
<dc:creator>Yixuan Zhang</dc:creator>
<dc:creator>Yuanli Huang</dc:creator>
<dc:creator>Nobel Chengong Zong</dc:creator>
<dc:creator>Ji Youn Youn</dc:creator>
<dc:creator>Wenhui Chen</dc:creator>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Joseph Loscalzo</dc:creator>
<dc:creator>Hua Cai</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR</dc:title>
<dc:identifier>pmid:38299369</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323090</dc:identifier>
</item>
<item>
<title>LncRNA CHKB-DT Downregulation Enhances Dilated Cardiomyopathy Through ALDH2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38299365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS: CHKB-DT is significantly downregulated in DCM. CHKB-DT acts as an energy metabolism-associated long noncoding RNA and represents a promising therapeutic target against DCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 1. doi: 10.1161/CIRCRESAHA.123.323428. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Human cardiac long noncoding RNA (lncRNA) profiles in patients with dilated cardiomyopathy (DCM) were previously analyzed, and the long noncoding RNA CHKB (choline kinase beta) divergent transcript (CHKB-DT) levels were found to be mostly downregulated in the heart. In this study, the function of CHKB-DT in DCM was determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Long noncoding RNA expression levels in the human heart tissues were measured via quantitative reverse transcription-polymerase chain reaction and in situ hybridization assays. A CHKB-DT heterozygous or homozygous knockout mouse model was generated using the clustered regularly interspaced palindromic repeat (CRISPR)/CRISPR-associated protein 9 system, and the adeno-associated virus with a cardiac-specific promoter was used to deliver the RNA in vivo. Sarcomere shortening was performed to assess the primary cardiomyocyte contractility. The Seahorse XF cell mitochondrial stress test was performed to determine the energy metabolism and ATP production. Furthermore, the underlying mechanisms were explored using quantitative proteomics, ribosome profiling, RNA antisense purification assays, mass spectrometry, RNA pull-down, luciferase assay, RNA-fluorescence in situ hybridization, and Western blotting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: CHKB-DT levels were remarkably decreased in patients with DCM and mice with transverse aortic constriction-induced heart failure. Heterozygous knockout of CHKB-DT in cardiomyocytes caused cardiac dilation and dysfunction and reduced the contractility of primary cardiomyocytes. Moreover, CHKB-DT heterozygous knockout impaired mitochondrial function and decreased ATP production as well as cardiac energy metabolism. Mechanistically, ALDH2 (aldehyde dehydrogenase 2) was a direct target of CHKB-DT. CHKB-DT physically interacted with the mRNA of ALDH2 and FUS (RNA-binding protein FUS) through the GGUG motif. CHKB-DT knockdown aggravated ALDH2 mRNA degradation and 4-hydroxy-2-nonenal production, whereas overexpression of CHKB-DT reversed these molecular changes. Furthermore, restoring ALDH2 expression in CHKB-DT<sup>+/</sup><sup>-</sup> mice alleviated cardiac dilation and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CHKB-DT is significantly downregulated in DCM. CHKB-DT acts as an energy metabolism-associated long noncoding RNA and represents a promising therapeutic target against DCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38299365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38299365</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323428>10.1161/CIRCRESAHA.123.323428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38299365</guid>
<pubDate>Thu, 01 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Xiang Nie</dc:creator>
<dc:creator>Jiahui Fan</dc:creator>
<dc:creator>Beibei Dai</dc:creator>
<dc:creator>Zheng Wen</dc:creator>
<dc:creator>Huaping Li</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:date>2024-02-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>LncRNA CHKB-DT Downregulation Enhances Dilated Cardiomyopathy Through ALDH2</dc:title>
<dc:identifier>pmid:38299365</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323428</dc:identifier>
</item>
<item>
<title>Reply: Risk Estimation in Valvular Heart Disease in Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):e49. doi: 10.1016/j.jacc.2023.11.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296409</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.023>10.1016/j.jacc.2023.11.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296409</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Anish Keepanasseril</dc:creator>
<dc:creator>Swaraj Nandini Pande</dc:creator>
<dc:creator>Santhosh Satheesh</dc:creator>
<dc:creator>Samuel C Siu</dc:creator>
<dc:creator>Rohan D'Souza</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Risk Estimation in Valvular Heart Disease in Pregnancy</dc:title>
<dc:identifier>pmid:38296409</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.023</dc:identifier>
</item>
<item>
<title>Risk Estimation in Valvular Heart Disease in Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):e47. doi: 10.1016/j.jacc.2023.10.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296408</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.051>10.1016/j.jacc.2023.10.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296408</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Boban Thomas</dc:creator>
<dc:creator>Vera Vaz Ferreira</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk Estimation in Valvular Heart Disease in Pregnancy</dc:title>
<dc:identifier>pmid:38296408</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.051</dc:identifier>
</item>
<item>
<title>Promoting Cardiovascular Health Equity: Association of Black Cardiologists Practical Model for Community-Engaged Partnerships</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296407/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):632-636. doi: 10.1016/j.jacc.2023.11.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296407/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296407</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.025>10.1016/j.jacc.2023.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296407</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Courtney Bess</dc:creator>
<dc:creator>Daphne Ferdinand</dc:creator>
<dc:creator>Paul Underwood</dc:creator>
<dc:creator>Donnell Ivy</dc:creator>
<dc:creator>Michelle A Albert</dc:creator>
<dc:creator>Anekwe Onwuanyi</dc:creator>
<dc:creator>Cassandra McCullough</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Association of Black Cardiologists Community Programs Committee</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Promoting Cardiovascular Health Equity: Association of Black Cardiologists Practical Model for Community-Engaged Partnerships</dc:title>
<dc:identifier>pmid:38296407</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.025</dc:identifier>
</item>
<item>
<title>Promises and Perils of Consumer Mobile Technologies in Cardiovascular Care: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>Direct-to-consumer (D2C) wearables are becoming increasingly popular in cardiovascular health management because of their affordability and capability to capture diverse health data. Wearables may enable continuous health care provider-patient partnerships and reduce the volume of episodic clinic-based care (thereby reducing health care costs). However, challenges arise from the unregulated use of these devices, including questionable data reliability, potential misinterpretation of information,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):611-631. doi: 10.1016/j.jacc.2023.11.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Direct-to-consumer (D2C) wearables are becoming increasingly popular in cardiovascular health management because of their affordability and capability to capture diverse health data. Wearables may enable continuous health care provider-patient partnerships and reduce the volume of episodic clinic-based care (thereby reducing health care costs). However, challenges arise from the unregulated use of these devices, including questionable data reliability, potential misinterpretation of information, unintended psychological impacts, and an influx of clinically nonactionable data that may overburden the health care system. Further, these technologies could exacerbate, rather than mitigate, health disparities. Experience with wearables in atrial fibrillation underscores these challenges. The prevalent use of D2C wearables necessitates a collaborative approach among stakeholders to ensure effective integration into cardiovascular care. Wearables are heralding innovative disease screening, diagnosis, and management paradigms, expanding therapeutic avenues, and anchoring personalized medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296406</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.024>10.1016/j.jacc.2023.11.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296406</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Niraj Varma</dc:creator>
<dc:creator>Janet K Han</dc:creator>
<dc:creator>Rod Passman</dc:creator>
<dc:creator>Lindsey Anne Rosman</dc:creator>
<dc:creator>Hamid Ghanbari</dc:creator>
<dc:creator>Peter Noseworthy</dc:creator>
<dc:creator>Jennifer N Avari Silva</dc:creator>
<dc:creator>Abhishek Deshmukh</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Gregory Lip</dc:creator>
<dc:creator>Arun R Sridhar</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Promises and Perils of Consumer Mobile Technologies in Cardiovascular Care: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38296406</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.024</dc:identifier>
</item>
<item>
<title>It Is Shocking How Little We Have Talked About Cardiogenic Shock in Pediatrics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):609-610. doi: 10.1016/j.jacc.2023.11.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296405</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.022>10.1016/j.jacc.2023.11.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296405</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kurt R Schumacher</dc:creator>
<dc:creator>Carolyn Vitale</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>It Is Shocking How Little We Have Talked About Cardiogenic Shock in Pediatrics</dc:title>
<dc:identifier>pmid:38296405</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.022</dc:identifier>
</item>
<item>
<title>Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS: CS occurs in 26% of pediatric hospitalizations for ADHF and is independently associated with hospital mortality. A modified Society for Cardiovascular Angiography and Interventions classification for CS severity showed robust association with increasing mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):595-608. doi: 10.1016/j.jacc.2023.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite growing cardiogenic shock (CS) research in adults, the epidemiology, clinical features, and outcomes of children with CS are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to describe the epidemiology, clinical presentation, hospital course, risk factors, and outcomes of CS among children hospitalized for acute decompensated heart failure (ADHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined consecutive ADHF hospitalizations (&lt;21 years of age) from a large single-center retrospective cohort. Patients with CS at presentation were analyzed and risk factors for CS and for the primary outcome of in-hospital mortality were identified. A modified Society for Cardiovascular Angiography and Interventions shock classification was created and patients were staged accordingly.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 803 hospitalizations for ADHF were identified in 591 unique patients (median age 7.6 years). CS occurred in 207 (26%) hospitalizations. ADHF hospitalizations with CS were characterized by worse systolic function (P = 0.040), higher B-type natriuretic peptide concentration (P = 0.032), and more frequent early severe renal (P = 0.023) and liver (P &lt; 0.001) injury than those without CS. Children presenting in CS received mechanical ventilation (87% vs 26%) and mechanical circulatory support (45% vs 16%) more frequently (both P &lt; 0.001). Analyzing only the most recent ADHF hospitalization, children with CS were at increased risk of in-hospital mortality compared with children without CS (28% vs 11%; OR: 1.91; 95% CI: 1.05-3.45; P = 0.033). Each higher CS stage was associated with greater inpatient mortality (OR: 2.40-8.90; all P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CS occurs in 26% of pediatric hospitalizations for ADHF and is independently associated with hospital mortality. A modified Society for Cardiovascular Angiography and Interventions classification for CS severity showed robust association with increasing mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296404</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.019>10.1016/j.jacc.2023.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296404</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kriti Puri</dc:creator>
<dc:creator>Jacob C Jentzer</dc:creator>
<dc:creator>Joseph A Spinner</dc:creator>
<dc:creator>Kyle D Hope</dc:creator>
<dc:creator>Iki Adachi</dc:creator>
<dc:creator>Sebastian C Tume</dc:creator>
<dc:creator>Hari P Tunuguntla</dc:creator>
<dc:creator>Swati Choudhry</dc:creator>
<dc:creator>Antonio G Cabrera</dc:creator>
<dc:creator>Jack F Price</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children</dc:title>
<dc:identifier>pmid:38296404</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.019</dc:identifier>
</item>
<item>
<title>Innovative Methods to Tackle Longstanding Goals in Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):592-594. doi: 10.1016/j.jacc.2023.11.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296403</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.020>10.1016/j.jacc.2023.11.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296403</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Innovative Methods to Tackle Longstanding Goals in Aortic Stenosis</dc:title>
<dc:identifier>pmid:38296403</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.020</dc:identifier>
</item>
<item>
<title>Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296402/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS: These findings identify MMP12 as a potential novel circulating biomarker of AS risk and C1QTNF1 as a new putative target to prevent AS progression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):577-591. doi: 10.1016/j.jacc.2023.11.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited data exist regarding risk factors for aortic stenosis (AS). The plasma proteome is a promising phenotype for discovery of novel biomarkers and potentially causative mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to discover novel biomarkers with potentially causal associations with AS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured 4,877 plasma proteins (SomaScan aptamer-affinity assay) among ARIC (Atherosclerosis Risk In Communities) study participants in mid-life (visit 3 [V3]; n = 11,430; age 60 ± 6 years) and in late-life (V5; n = 4,899; age 76 ± 5 years). We identified proteins cross-sectionally associated with aortic valve (AV) peak velocity (AVmax) and dimensionless index by echocardiography at V5 and with incident AV-related hospitalization after V3 with the use of multivariable linear and Cox proportional hazard regression. We assessed associations of candidate proteins with changes in AVmax over 6 years and with AV calcification with the use of cardiac computed tomography, replicated analysis in an independent sample, performed Mendelian randomization, and evaluated gene expression in explanted human AV tissue.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fifty-two proteins cross-sectionally were associated with AVmax and dimensionless index at V5 and with risk of incident AV-related hospitalization after V3. Among 3,413 participants in the Cardiovascular Health Study, 6 of those proteins were significantly associated with adjudicated moderate or severe AS, including matrix metalloproteinase 12 (MMP12), complement C1q tumor necrosis factor-related protein 1 (C1QTNF1), and growth differentiation factor-15. MMP12 was also associated with greater increase in AVmax over 6 years, greater degree of AV calcification, and greater expression in calcific compared with normal or fibrotic AV tissue. C1QTNF1 had consistent potential causal effects on both AS and AVmax according to Mendelian randomization analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify MMP12 as a potential novel circulating biomarker of AS risk and C1QTNF1 as a new putative target to prevent AS progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296402/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296402</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.021>10.1016/j.jacc.2023.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296402</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Khaled Shelbaya</dc:creator>
<dc:creator>Victoria Arthur</dc:creator>
<dc:creator>Yimin Yang</dc:creator>
<dc:creator>Pranav Dorbala</dc:creator>
<dc:creator>Leo Buckley</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Line Dufresne</dc:creator>
<dc:creator>Ta-Yu Yang</dc:creator>
<dc:creator>James C Engert</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>James Floyd</dc:creator>
<dc:creator>Thomas R Austin</dc:creator>
<dc:creator>Anna Bortnick</dc:creator>
<dc:creator>Jorge Kizer</dc:creator>
<dc:creator>Renata C C Freitas</dc:creator>
<dc:creator>Sasha A Singh</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis</dc:title>
<dc:identifier>pmid:38296402</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.021</dc:identifier>
</item>
<item>
<title>Redefining Cardiovascular Risk Assessment as a Spectrum: From Binary to Continuous</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):574-576. doi: 10.1016/j.jacc.2023.11.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296401</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.026>10.1016/j.jacc.2023.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296401</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Pier Sergio Saba</dc:creator>
<dc:creator>Sadeer Al Kindi</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Redefining Cardiovascular Risk Assessment as a Spectrum: From Binary to Continuous</dc:title>
<dc:identifier>pmid:38296401</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.026</dc:identifier>
</item>
<item>
<title>Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296400/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS: A universal risk prediction approach performed well in persons with and without ASCVD. This approach could facilitate the transition from primary to secondary prevention by streamlining risk classification and discussion between clinicians and patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):562-573. doi: 10.1016/j.jacc.2023.11.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: American College of Cardiology/American Heart Association guidelines recommend distinct risk classification systems for primary and secondary cardiovascular disease prevention. However, both systems rely on similar predictors (eg, age and diabetes), indicating the possibility of a universal risk prediction approach for major adverse cardiovascular events (MACEs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors examined the performance of predictors in persons with and without atherosclerotic cardiovascular disease (ASCVD) and developed and validated a universal risk prediction model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 9,138 ARIC (Atherosclerosis Risk In Communities) participants with (n = 609) and without (n = 8,529) ASCVD at baseline (1996-1998), we examined established predictors in the risk classification systems and other predictors, such as body mass index and cardiac biomarkers (troponin and natriuretic peptide), using Cox models with MACEs (myocardial infarction, stroke, and heart failure). We also evaluated model performance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a follow-up of approximately 20 years, there were 3,209 MACEs (2,797 for no prior ASCVD). Most predictors showed similar associations with MACE regardless of baseline ASCVD status. A universal risk prediction model with the predictors (eg, established predictors, cardiac biomarkers) identified by least absolute shrinkage and selection operator regression and bootstrapping showed good discrimination for both groups (c-statistics of 0.747 and 0.691, respectively), and risk classification and showed excellent calibration, irrespective of ASCVD status. This universal prediction approach identified individuals without ASCVD who had a higher risk than some individuals with ASCVD and was validated externally in 5,322 participants in the MESA (Multi-Ethnic Study of Atherosclerosis).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A universal risk prediction approach performed well in persons with and without ASCVD. This approach could facilitate the transition from primary to secondary prevention by streamlining risk classification and discussion between clinicians and patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296400/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296400</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.028>10.1016/j.jacc.2023.11.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296400</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yejin Mok</dc:creator>
<dc:creator>Zeina Dardari</dc:creator>
<dc:creator>Yingying Sang</dc:creator>
<dc:creator>Xiao Hu</dc:creator>
<dc:creator>Michael P Bancks</dc:creator>
<dc:creator>Lena Mathews</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Silvia Koton</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Wayne Rosamond</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease</dc:title>
<dc:identifier>pmid:38296400</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.028</dc:identifier>
</item>
<item>
<title>A Post Hoc Analysis of ISCHEMIA: Are All Events Created Equal?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):559-561. doi: 10.1016/j.jacc.2023.11.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38296399</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.027>10.1016/j.jacc.2023.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296399</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>J Michael DiMaio</dc:creator>
<dc:creator>Kyle A McCullough</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Post Hoc Analysis of ISCHEMIA: Are All Events Created Equal?</dc:title>
<dc:identifier>pmid:38296399</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.027</dc:identifier>
</item>
<item>
<title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38295787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>Streptococcus anginosus (S. anginosus) was enriched in the gastric mucosa of patients with gastric cancer (GC). Here, we show that S. anginosus colonized the mouse stomach and induced acute gastritis. S. anginosus infection spontaneously induced progressive chronic gastritis, parietal cell atrophy, mucinous metaplasia, and dysplasia in conventional mice, and the findings were confirmed in germ-free mice. In addition, S. anginosus accelerated GC progression in carcinogen-induced gastric...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 22:S0092-8674(24)00006-0. doi: 10.1016/j.cell.2024.01.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Streptococcus anginosus (S. anginosus) was enriched in the gastric mucosa of patients with gastric cancer (GC). Here, we show that S. anginosus colonized the mouse stomach and induced acute gastritis. S. anginosus infection spontaneously induced progressive chronic gastritis, parietal cell atrophy, mucinous metaplasia, and dysplasia in conventional mice, and the findings were confirmed in germ-free mice. In addition, S. anginosus accelerated GC progression in carcinogen-induced gastric tumorigenesis and YTN16 GC cell allografts. Consistently, S. anginosus disrupted gastric barrier function, promoted cell proliferation, and inhibited apoptosis. Mechanistically, we identified an S. anginosus surface protein, TMPC, that interacts with Annexin A2 (ANXA2) receptor on gastric epithelial cells. Interaction of TMPC with ANXA2 mediated attachment and colonization of S. anginosus and induced mitogen-activated protein kinase (MAPK) activation. ANXA2 knockout abrogated the induction of MAPK by S. anginosus. Thus, this study reveals S. anginosus as a pathogen that promotes gastric tumorigenesis via direct interactions with gastric epithelial cells in the TMPC-ANXA2-MAPK axis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38295787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38295787</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.004>10.1016/j.cell.2024.01.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38295787</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kaili Fu</dc:creator>
<dc:creator>Alvin Ho Kwan Cheung</dc:creator>
<dc:creator>Chi Chun Wong</dc:creator>
<dc:creator>Weixin Liu</dc:creator>
<dc:creator>Yunfei Zhou</dc:creator>
<dc:creator>Feixue Wang</dc:creator>
<dc:creator>Pingmei Huang</dc:creator>
<dc:creator>Kai Yuan</dc:creator>
<dc:creator>Olabisi Oluwabukola Coker</dc:creator>
<dc:creator>Yasi Pan</dc:creator>
<dc:creator>Danyu Chen</dc:creator>
<dc:creator>Nga Man Lam</dc:creator>
<dc:creator>Mengxue Gao</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>He Huang</dc:creator>
<dc:creator>Ka Fai To</dc:creator>
<dc:creator>Joseph Jao Yiu Sung</dc:creator>
<dc:creator>Jun Yu</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</dc:title>
<dc:identifier>pmid:38295787</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.004</dc:identifier>
</item>
<item>
<title>What Is Your Secret to Health?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38294819</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5344>10.1001/jamacardio.2023.5344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294819</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Rebecca Ann Levine</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What Is Your Secret to Health?</dc:title>
<dc:identifier>pmid:38294819</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5344</dc:identifier>
</item>
<item>
<title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201211429&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5372. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support might be limited, partly due to lack of external validation, marginal predictive power, and absence of intraoperative characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To derive and validate a risk model to predict RVF after LVAD implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a hybrid prospective-retrospective multicenter cohort study conducted from April 2008 to July 2019 of patients with advanced heart failure (HF) requiring continuous-flow LVAD. The derivation cohort included patients enrolled at 5 institutions. The external validation cohort included patients enrolled at a sixth institution within the same period. Study data were analyzed October 2022 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Study participants underwent chronic continuous-flow LVAD support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary outcome was RVF incidence, defined as the need for RV assist device or intravenous inotropes for greater than 14 days. Bootstrap imputation and adaptive least absolute shrinkage and selection operator variable selection techniques were used to derive a predictive model. An RVF risk calculator (STOP-RVF) was then developed and subsequently externally validated, which can provide personalized quantification of the risk for LVAD candidates. Its predictive accuracy was compared with previously published RVF scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The derivation cohort included 798 patients (mean [SE] age, 56.1 [13.2] years; 668 male [83.7%]). The external validation cohort included 327 patients. RVF developed in 193 of 798 patients (24.2%) in the derivation cohort and 107 of 327 patients (32.7%) in the validation cohort. Preimplant variables associated with postoperative RVF included nonischemic cardiomyopathy, intra-aortic balloon pump, microaxial percutaneous left ventricular assist device/venoarterial extracorporeal membrane oxygenation, LVAD configuration, Interagency Registry for Mechanically Assisted Circulatory Support profiles 1 to 2, right atrial/pulmonary capillary wedge pressure ratio, use of angiotensin-converting enzyme inhibitors, platelet count, and serum sodium, albumin, and creatinine levels. Inclusion of intraoperative characteristics did not improve model performance. The calculator achieved a C statistic of 0.75 (95% CI, 0.71-0.79) in the derivation cohort and 0.73 (95% CI, 0.67-0.80) in the validation cohort. Cumulative survival was higher in patients composing the low-risk group (estimated &lt;20% RVF risk) compared with those in the higher-risk groups. The STOP-RVF risk calculator exhibited a significantly better performance than commonly used risk scores proposed by Kormos et al (C statistic, 0.58; 95% CI, 0.53-0.63) and Drakos et al (C statistic, 0.62; 95% CI, 0.57-0.67).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201211429&v=2.18.0">38294795</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5372>10.1001/jamacardio.2023.5372</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294795</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Iosif Taleb</dc:creator>
<dc:creator>Christos P Kyriakopoulos</dc:creator>
<dc:creator>Robyn Fong</dc:creator>
<dc:creator>Naila Ijaz</dc:creator>
<dc:creator>Zachary Demertzis</dc:creator>
<dc:creator>Konstantinos Sideris</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Antigone G Koliopoulou</dc:creator>
<dc:creator>Michael J Bonios</dc:creator>
<dc:creator>Rohan Shad</dc:creator>
<dc:creator>Adithya Peruri</dc:creator>
<dc:creator>Thomas C Hanff</dc:creator>
<dc:creator>Elizabeth Dranow</dc:creator>
<dc:creator>Theodoros V Giannouchos</dc:creator>
<dc:creator>Ethan Krauspe</dc:creator>
<dc:creator>Cyril Zakka</dc:creator>
<dc:creator>Daniel G Tang</dc:creator>
<dc:creator>Hassan W Nemeh</dc:creator>
<dc:creator>Josef Stehlik</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Rami Alharethi</dc:creator>
<dc:creator>William T Caine</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>William Hiesinger</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</dc:title>
<dc:identifier>pmid:38294795</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5372</dc:identifier>
</item>





























</channel>
</rss>